Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.2963 +0.0163 (+5.82%)
Streaming Delayed Price Updated: 12:17 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 Next >
CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From CytoDyn Inc.
Via GlobeNewswire
A Penny Stock To Watch In Challenging Cancer Space
The author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its current price of around $0.32. 
Via Benzinga
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health 
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Releases ESMO Breast Cancer Meeting Poster
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
From CytoDyn Inc.
Via GlobeNewswire
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
CytoDyn represents a speculative bet on a once-celebrated drug that is now steadily rebuilding its case. If leronlimab can fulfill its early promise in metastatic triple-negative breast cancer, the... 
Via Talk Markets
Topics Stocks / Equities
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics
Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028). 
Via Talk Markets
Topics Government Stocks / Equities
March 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
December 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
September 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Settlement with Amarex Clinical Research LLC
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn to Host Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
May 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.